View:
Download DOC
Download PDF
Download XLS
FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported) April 25, 2006

 

Nabi Biopharmaceuticals

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

 

000-04829   59-1212264
(Commission File Number)   (IRS Employer Identification No.)

 

5800 Park of Commerce Boulevard N.W., Boca Raton, FL   33487
(Address of Principal Executive Offices)   (Zip Code)

(561) 989-5800

(Registrant’s Telephone Number, Including Area Code)

 

 

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Item 8.01 Other Events

On April 25, 2006, Nabi Biopharmaceuticals sent a letter to Knott Partners Management, LLC. The text of the letter is furnished as Exhibit 99 hereto.

Item 9.01. Financial Statements and Exhibits

 

Exhibit
number		  

Description

99   Letter from Nabi Biopharmaceuticals to Knott Partners Management, LLC, dated April 25, 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

   

NABI BIOPHARMACEUTICALS

Date: April 25, 2006    

By:

   /s/ Thomas H. McLain
     

Name:

  

Thomas H. McLain

     

Title:

  

Chairman, Chief Executive Officer, and President

 

 

 

LETTER FROM NABI BIOPHARMACEUTICALS

Exhibit 99

April 25, 2006

Via Facsimile and Overnight Delivery

Anthony R. Campbell

General Partner

Knott Partners Management, LLC

485 Underhill Boulevard, Suite 205

Syosset, New York 11791

Dear Tony,

We are in receipt of your letter dated April 19, 2006. We take our shareholders’ views seriously and appreciate your opinions.

As I have told you previously, we are committed to follow-up on every call we receive from any and all companies or organizations who express interest in a collaboration or alliance with Nabi Biopharmaceuticals. Your letter stated that we have previously ignored phone calls from major companies seeking to buy Nabi Biopharmaceuticals. To my knowledge that statement is factually inaccurate. As you are also aware, it is not our practice to discuss potential transactions or rumors about transactions. However, I believe it is important to correct the record in this particular instance. Our Board takes its fiduciary duties to all of our shareholders seriously and we are always open to considering ideas that would enhance shareholder value.

Please note that we undertake no further obligation to update you or any of our other shareholders on the matters discussed in this letter.

Thank you for your interest in our company.

 

Sincerely,

/s/ Thomas H. McLain

Thomas H. McLain